vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Good Times Restaurants Inc. (GTIM). Click either name above to swap in a different company.
Good Times Restaurants Inc. is the larger business by last-quarter revenue ($32.7M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). Good Times Restaurants Inc. runs the higher net margin — 0.6% vs -0.8%, a 1.4% gap on every dollar of revenue. On growth, Good Times Restaurants Inc. posted the faster year-over-year revenue change (-10.0% vs -25.7%). Good Times Restaurants Inc. produced more free cash flow last quarter ($1.2M vs $-15.8M). Over the past eight quarters, Good Times Restaurants Inc.'s revenue compounded faster (-0.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Good Times is a Golden, Colorado–based fast-food restaurant specializing in premium burgers and frozen custard. As of July 2023, the chain operates 31 locations, down from 38 in 2015.
CTMX vs GTIM — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $32.7M |
| Net Profit | $-154.0K | $181.0K |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 0.9% |
| Net Margin | -0.8% | 0.6% |
| Revenue YoY | -25.7% | -10.0% |
| Net Profit YoY | 97.6% | 10.4% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $32.7M | ||
| Q3 25 | — | $37.0M | ||
| Q2 25 | $18.7M | $34.3M | ||
| Q1 25 | $50.9M | — | ||
| Q4 24 | $38.1M | $36.3M | ||
| Q3 24 | $33.4M | $35.8M | ||
| Q2 24 | $25.1M | $38.0M | ||
| Q1 24 | $41.5M | $35.4M |
| Q4 25 | — | $181.0K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-154.0K | $-624.0K | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $18.9M | $164.0K | ||
| Q3 24 | $5.7M | $230.0K | ||
| Q2 24 | $-6.5M | $1.3M | ||
| Q1 24 | $13.8M | $618.0K |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 3.3% | ||
| Q2 25 | -6.9% | -1.5% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | 0.2% | ||
| Q3 24 | 12.3% | -0.3% | ||
| Q2 24 | -33.7% | 3.2% | ||
| Q1 24 | 28.1% | 1.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | -0.8% | -1.8% | ||
| Q1 25 | 46.2% | — | ||
| Q4 24 | 49.6% | 0.5% | ||
| Q3 24 | 17.2% | 0.6% | ||
| Q2 24 | -26.0% | 3.5% | ||
| Q1 24 | 33.3% | 1.7% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $0.14 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $0.01 | ||
| Q2 24 | — | $0.12 | ||
| Q1 24 | — | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $33.2M |
| Total Assets | $175.1M | $82.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | $2.7M | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | $3.0M | ||
| Q3 24 | $40.6M | $3.9M | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | $4.0M |
| Q4 25 | — | $33.2M | ||
| Q3 25 | — | $33.1M | ||
| Q2 25 | $119.9M | $31.6M | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $-456.0K | $32.4M | ||
| Q3 24 | $-23.5M | $32.4M | ||
| Q2 24 | $-31.2M | $32.3M | ||
| Q1 24 | $-31.7M | $31.6M |
| Q4 25 | — | $82.5M | ||
| Q3 25 | — | $85.8M | ||
| Q2 25 | $175.1M | $86.9M | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $120.5M | $89.5M | ||
| Q3 24 | $139.0M | $87.1M | ||
| Q2 24 | $159.2M | $90.1M | ||
| Q1 24 | $184.7M | $89.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $1.4M |
| Free Cash FlowOCF − Capex | $-15.8M | $1.2M |
| FCF MarginFCF / Revenue | -84.6% | 3.8% |
| Capex IntensityCapex / Revenue | 0.1% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 7.85× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-72.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | $-15.8M | $714.0K | ||
| Q1 25 | $-21.0M | — | ||
| Q4 24 | $-19.9M | $-518.0K | ||
| Q3 24 | $-20.7M | $394.0K | ||
| Q2 24 | $-19.5M | $3.2M | ||
| Q1 24 | $-26.0M | $1.8M |
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $735.0K | ||
| Q2 25 | $-15.8M | $-105.0K | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | $-1.9M | ||
| Q3 24 | $-20.7M | $-466.0K | ||
| Q2 24 | $-19.6M | $2.0M | ||
| Q1 24 | $-26.2M | $1.2M |
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | -84.6% | -0.3% | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | -5.3% | ||
| Q3 24 | -62.1% | -1.3% | ||
| Q2 24 | -78.2% | 5.3% | ||
| Q1 24 | -63.1% | 3.2% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | 0.1% | 2.4% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 3.9% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.3% | 1.7% |
| Q4 25 | — | 7.85× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | -3.16× | ||
| Q3 24 | -3.61× | 1.71× | ||
| Q2 24 | — | 2.44× | ||
| Q1 24 | -1.89× | 2.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
GTIM
Segment breakdown not available.
